Implementing a SARS-CoV-2 Test in Your Laboratory

In the rapidly evolving landscape for diagnostic testing for the SARS-CoV-2 virus, the CAP can help clarify and simplify the rules of compliance so that you can efficiently and safely introduce testing in your laboratory to serve your patients during this public health emergency.

COVID-19 Diagnostic Tests

You can use the links below to see a current list of COVID-19 tests approved via the US FDA’s Emergency Use Authorization and the WHO’s Emergency Use Listing:

United States:
https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd

Worldwide:
https://www.who.int/diagnostics_laboratory/EUL/en/

Laboratories subject to US regulations, may only use:
- Tests authorized through the FDA’s EUA process
- Tests developed by the laboratory with submission for EUA
- Tests authorized by the state where the laboratory is located

Validated tests that will be submitted to the FDA for EUA may be distributed and used prior to obtaining EUA under the conditions define by the FDA. Review the FDA policy for more information.

International laboratories (not subject to US regulations) may use the following types of tests, if allowed by country and regional regulations and guidelines:
- Tests authorized through the FDA's EUA process
- Tests listed on the World Health Organization Emergency Use Listing (EUL)
- Tests approved by internationally recognized regulatory authorities (eg, CE-Marking)

Visit cap.org for the latest COVID-19 information and updates.
While the ultimate objective is to fully verify the method performance of the assay, the pandemic crisis, the urgent need for patient testing, and the possible lack of reagents and supplies make it difficult to fully evaluate the accuracy, precision, and reportable range as stated in COM.40300. A more limited approach may be acceptable. You and your laboratory director should determine the depth of verification needed to begin testing and your laboratory director must approve the method verification prior to testing (COM.40475).

The test kits may have QC materials for checking performance of the test kit. For accuracy verification (COM.40300), laboratories may use known positive and negative patient specimens, positive and negative QC materials, and other commercially purchased materials. Patient specimens can be altered (eg. spiked with control materials). The CAP encourages laboratories to continue to evaluate assay performance as testing continues and more positive specimens become available for verification studies.

For Analytic Interferences (COM.40500) the kit manufacturer or CDC may be able to provide a list of interfering substances.

Download a template for analytical verification by searching “analytic verification” at cap.org (login required).

Laboratories that develop their own assays are required to perform a complete validation study (refer to the section below on Laboratory-Developed Tests).

### International Laboratories Test Verification Options

The instructions above for test method verification also apply to laboratories not subject to US regulations that are using FDA EUA assays. In addition, it applies to:

- Tests listed on the WHO EUL
- Tests approved by internationally recognized regulatory authorities (eg, CE-Marking)

Laboratories that develop their own assays or obtain test kits through unapproved or unauthorized sources are required to perform a complete validation study (refer to the section below on Laboratory-Developed Tests).
Modifications to Approved/Authorized Test Kits

There have been shortages of certain types of supplies and equipment needed for specimen collection and testing (e.g., transport medium, swabs) for COVID-19 EUA assays. The FDA provides recommendations in its frequently asked questions for alternative products that may be used based on the best available evidence and in consultation with outside experts. The FDA recommendations are updated as the FDA receives more information from laboratories and manufacturers on other validated alternatives.

Laboratories may also validate other alternatives. This can be accomplished through the use of a bridging study where the new component is evaluated for equivalent performance using parallel testing of the same specimens with new and original components.

Validation of Laboratory-Developed Tests

Laboratories developing tests for COVID-19 must establish accuracy, precision, reportable range, reference intervals, analytical sensitivity, and analytical specificity (interferences), as applicable. The tests must be validated at the laboratory performing the test.

Applicable checklist requirements include:

<table>
<thead>
<tr>
<th>Checklist</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>COM.40350 Validation of Test Performance Specifications - Modified FDA-cleared/approved and LDTs</td>
<td></td>
</tr>
<tr>
<td>COM.40475 Method Validation and Verification Approval - Nonwaived Tests</td>
<td></td>
</tr>
<tr>
<td>COM.40500 Analytical Interferences</td>
<td></td>
</tr>
<tr>
<td>COM.40830 Test List - Modified FDA-cleared/approved and LDTs</td>
<td></td>
</tr>
<tr>
<td>COM.40840 Calibration and Quality Control Procedures - Modified FDA-cleared/approved and LDTs</td>
<td></td>
</tr>
<tr>
<td>COM.40640 Clinical Claims Validation</td>
<td></td>
</tr>
<tr>
<td>COM.40850 LDT and Class I ASR Reporting</td>
<td></td>
</tr>
</tbody>
</table>

Download a template for analytical validation by searching “analytic validation” at cap.org (login required).

Personnel Qualifications for COVID-19 Testing

Review the personnel qualifications defined in the Laboratory General Checklist (GEN.54750) to identify the qualifications needed to perform testing in your laboratory.

The applicable personnel requirements are based on the complexity of the test performed.

- Tests approved under the FDA’s EUA process do not have test complexity assigned directly by the FDA; however, the Letter of Authorization for each EUA assay defines the setting in which the test may be used. Many are authorized for use in moderate and high complexity laboratories. If a test is also authorized for use in a point-of-care setting, it is deemed to be CLIA waived.
  - Review the Letter of Authorization on the FDA website for each test performed by your laboratory and ensure that personnel meet applicable qualifications.
- State-authorized assays, WHO EUL assays, and laboratory-developed tests are considered high complexity testing.
- COVID-19 serology assays that have not been through an EUA approval process are considered high complexity testing.
Quality Control or IQCP for COVID-19 tests?

The following is the CAP’s current guidance for performing quality control for COVID-19 testing during the COVID-19 health care crisis:

- For EUA tests **authorized for use in a patient care setting**, perform quality control following the manufacturer's instructions, at minimum. The FDA deems these tests to be CLIA waived tests. No IQCP is required.

- For EUA tests **authorized for use by moderate or high complexity laboratories only**, perform quality control following the manufacturer’s instructions, at minimum. These tests are considered to be nonwaived tests; however, no IQCP is required **unless** the manufacturer does not define conditions for reduced external QC frequency in its instructions for use.

If the manufacturer does not define conditions for reduced external quality control in its instructions for use (e.g., states to perform external QC in accordance with applicable federal, state, or local accreditation requirements), the laboratory must:

- Perform external QC following the default CLIA frequency (e.g., two levels of QC each day of testing) **OR**
- Implement an IQCP if it wishes to reduce the frequency of external QC. Written QC plans must be approved by the laboratory director prior to implementation.

Please note that all laboratories performing nonwaived testing must perform external QC with each new lot and shipment of reagents.

Visit the CAP’s IQCP Toolbox for resources to develop an IQCP by logging into e-LAB Solutions Suite and searching for “IQCP Toolbox.”

How Can we do Proficiency Testing?

The CAP has a new **PT Program for COVID-19 testing** for the detection of SARS-CoV-2 by nucleic acid amplification testing.

- Each mailing will include three samples
- Samples are non-infectious and target gene regions N, E, RdRp, S, and ORF1a.
- It will include two mailings for 2020 with the first shipping on May 18, 2020.

You can order the program today in the [online store](#) or by contacting the CAP at 800-323-4040. It is only available for customers located in the US and US territories (e.g., Guam, Puerto Rico) at this time.

The CAP is also looking at developing proficiency testing for serological COVID-19 testing.

Alternatively, your laboratory must perform alternative performance assessment to determine the reliability of analytic testing at least semiannually. Review COM.01500 for more detail on performing an alternative performance assessment.
How to Add a COVID-19 Test to the CAP Activity Menu?

Update your laboratory’s activity menu in Organizational Profile by logging into e-LAB Solutions Suite on cap.org. For more detailed information on adding COVID-19 activities, see the COVID-19 Q &A.

The following activities are being used to identify COVID-19 assays:

- Molecular-based assays:
  - nCOV 2019, NAA, EUA, non-waived
  - nCOV 2019, NAA, EUA, LDT
  - nCOV 2019, NAA, EUA, waived*
  - nCOV 2019, NAA, EUA, waived, POCT*

- Serological assays:
  - nCOV 2019 antibodies

*The waived activities may only be used for assays that have received authorization by the FDA for use in the patient care setting. Assays that have only received authorization for CLIA-certified moderate and high complexity laboratories must use the non-waived activity, even if the test is performed in a patient care setting.

If you are unsure how your laboratory’s test was authorized, review the EUA Letter of Authorization for your specific test on the FDA website.

Analytical Verification/Validation

<table>
<thead>
<tr>
<th>VERIFICATION:</th>
<th>VALIDATION:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Precision</td>
<td>• Precision</td>
</tr>
<tr>
<td>• Accuracy</td>
<td>• Accuracy</td>
</tr>
<tr>
<td>• Reportable Range</td>
<td>• Reportable Range</td>
</tr>
<tr>
<td>• Reference Interval</td>
<td>• Reference Interval(s)</td>
</tr>
<tr>
<td>Mnemonic: PARR</td>
<td>• Analytical Sensitivity (LOD)</td>
</tr>
<tr>
<td></td>
<td>• Analytical Specificity (Interferences)</td>
</tr>
<tr>
<td></td>
<td>• Establish calibration and control procedures</td>
</tr>
<tr>
<td></td>
<td>• Other performance criteria</td>
</tr>
</tbody>
</table>

Mnemonic: PARR + AS + AS


Visit cap.org for the latest COVID-19 information and updates.